PA Volberding, RT Mitsuyasu, JP Golando, … - CA A Cancer Journal … - interscience.wiley.com The activity of the alpha interferons against AIDS-related Kaposi's sarcoma (KS) has been demonstrated
in numerous clinical trials. Unfortunately, most reports have involved small patient cohorts and
a variety of dosages and schedules of administration. We report here a series of Phase II ... Cited by 57 - Related articles - All 2 versions
L Vrang, H Bazin, G Remaud, J Chattopadhyaya, B … - Antiviral research, 1987 - boc.uu.se 3'-Azido-3'-deoxythymidine triphosphate (erythro) and its threo isomer were synthesized and
investigated for their inhibition of HIV reverse transcriptase from virus isolate U 937/HTLV-III.
The erythro isomer was a competitive inhibitor of the reaction directed by (rA)n(dT)12_18 ... Cited by 45 - Related articles - View as HTML - All 4 versions
- ►nih.gov [PDF] A Phillips, MA Wainberg, R Coates, M … - CMAJ: Canadian …, 1989 - pubmedcentral.nih.gov Eight patients with AIDS (acquired immune deficiency syndrome) but free of life-threatening infection
were treated with the immunosuppres- sive drug cyclosporine for a mean of 53.9 days. The serum
cyclosporine levels were maintained in the desired therapeutic range. All eight pa- tients ... Cited by 41 - Related articles - All 10 versions
JE Groopman - CA A Cancer Journal for Clinicians - interscience.wiley.com Kaposi's sarcoma, once a rarely seen neoplasm in the West, now occurs in an epidemic fashion
in association with acquired immune deficiency syndrome (AIDS). The pathogenesis of Kaposi's
sarcoma is still unclear but it appears to be an endothelial neoplasm. Its clinical ... Cited by 26 - Related articles - All 2 versions
RA Mayer, PA Sergios, K Coonan, LO'Brien - Eur. J. Clin. Invest, 1992 - interscience.wiley.com Abstract. Twenty patients with the acquired immunodeficiency syndrome (AIDS), AIDS-related
complex (ARC) or asymptomatic HIV infection (HIV +) were given 20 meg kg -3 trichosanthin
(TCS; 'Compound Q'), a ribosome-inactivating protein with in vitro antiviral activity against ... Cited by 23 - Related articles - All 4 versions
KH Mayer - L. Med. & Health Care, 1986 - heinonlinebackup.com Researchers trying to resolve the questions surrounding the AIDS epidemic may feel like Hercules
trying to slay the Hydra: for every head that is cut off, two new ones grow in its place. Doctors
have never treated their pa- tients in a social vacuum, but the expectations and anx- ieties ... Cited by 12 - Related articles - All 3 versions
L Resnick, PD Markham, K Veren, SZ Salahuddin, … - The Journal of infectious …, 1986 - jstor.org The discovery of HTLV-III/LAV (a cytopathic member of the human T lymphotropic retrovirus
[HTLV] family) and its identification as the etiologic agent of AIDS and its prodromes now permits
the consideration of therapy directed against this underlying causative agent [1,2]. Using ... Cited by 11 - Related articles - All 3 versions
- ►nih.gov [PDF] MA Wainberg, O Kendall, N Gilmore - CMAJ: Canadian Medical …, 1988 - pubmedcentral.nih.gov Human immunodeficiency virus type 1 (HIV-1) has been clearly associated with a variety of new
illnesses, including profound immunodefi- ciency (acquired immune deficiency syndrome
[AIDS]), wasting syndromes (formerly termed AIDS-related complex [ARC]) and ... Cited by 8 - Related articles - All 10 versions
- ►nih.gov [PDF] W Barcellini, PL Meroni, D Frasca, C … - Clinical and …, 1987 - pubmedcentral.nih.gov The effect of thymopentin treatmenton the immune defects in drugaddicts with persistent generalized
lymphadenopathy and HTLV-III infection was investigated. Thymopentin was administered subcutaneously
at two different dose schedules: 50 mg three times a week for 3 weeks (first cycle) and 50 ... Cited by 9 - Related articles - All 4 versions
